On October 15, Recursion Pharmaceuticals, Inc. rose 8.42% in Regular Trading, trading at $4.055/share, with turnover of $82.1027 million.
The move followed two company updates released the same day: Recursion Pharmaceuticals, Inc. priced a 61.5 million-share offering at $3.25 per share for gross proceeds of about $200 million, and said Sanofi selected the first drug candidate from their collaboration, triggering a $10 million milestone payment.
According to the company, total upfront and milestone payments under the Sanofi collaboration have now reached $144 million, with eligibility for more than $300 million in additional milestones plus double-digit royalties on net sales if approved. The inflammatory-disease candidate has moved into Sanofi’s pipeline and is expected to enter a phase 1 clinical study in 2027. The financing and collaboration progress together appear to be the clearest disclosed catalysts around the session’s stock move.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments